Finland grants emergency authorisation to Amplidiag COVID-19 test

Mobidiag’s Amplidiag COVID-19 molecular diagnostic test for the rapid detection of the virus has received emergency use authorisation in Finland, and the same process to gain emergency use authorisation is underway in the UK, France and Sweden. The test facilitates qualitative determination of SARS-CoV-2 from nasopharyngeal swabs and based on high-throughput PCR technology, it can process 48 samples in under three hours. It is now available in Finland exclusively to healthcare professionals as an emergency use test and doubles the current testing capacity. It will be routinely used at the main clinical laboratories of Helsinki University Hospital, SYNLAB and Mehiläinen.

CEO of Mobidiag, Tuomas Tenkanen, said: “At Mobidiag, we recognise that we have a responsibility to support healthcare systems during this extraordinary situation and we are focusing our efforts in this endeavour. There is an urgent and growing need for reliable diagnostic solutions for the early detection of COVID-19, and Mobidiag has been able to leverage its capabilities and existing technologies to develop new diagnostic solutions quickly. We are extremely pleased to bring our first diagnostic solution to the main clinical laboratories in Finland for large volume screening of COVID-19 and look forward to offering tests internationally in due course.”